Scientific Director
Immunologix Labs
Tampa, Florida
Chris has over two decades of experience in drug development within large pharmaceutical and biotech companies, specializing in the creation and execution of strategies for both biomarker and bioanalytical development. Trained as an immunologist, Chris has extensive expertise in immunogenicity and has played a pivotal role in developing the widely utilized immunogenicity risk assessment framework.
Chris's additional proficiency spans biomarker and bioanalytical assays across various disease areas and therapeutic modalities, including protein therapeutics, antisense oligonucleotides, and gene therapy. His drug development experience encompasses research through clinical development, protocol development, study reporting, regulatory filings, and post-marketing responses.
Chris is known for his exceptional ability to work with project teams, identifying critical questions and decision points, and delivering strategies that lead to efficient program execution. He has a significant industry presence, regularly speaking at bioanalytical and biomarker-focused meetings and has contributed to multiple industry white papers.
Disclosure information not submitted.
Implementing a Risk-Based Immunogenicity Strategy to Accelerate ASO Drug Development
Monday, May 5, 2025
10:00 AM - 10:30 AM ET